These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36674409)

  • 1. The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study.
    Tran TN; Hoeck S; De Schutter H; Janssens S; Peeters M; Van Hal G
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Tran TN; Peeters M; Hoeck S; Van Hal G; Janssens S; De Schutter H
    Br J Cancer; 2022 Apr; 126(7):1091-1099. PubMed ID: 35022524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers.
    Chiu HM; Jen GH; Wang YW; Fann JC; Hsu CY; Jeng YC; Yen AM; Chiu SY; Chen SL; Hsu WF; Lee YC; Wu MS; Wu CY; Jou YY; Chen TH
    Gut; 2021 Dec; 70(12):2321-2329. PubMed ID: 33495268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do socioeconomic factors play a role in nonadherence to follow-up colonoscopy after a positive faecal immunochemical test in the Flemish colorectal cancer screening programme?
    Hoeck S; van de Veerdonk W; De Brabander I
    Eur J Cancer Prev; 2020 Mar; 29(2):119-126. PubMed ID: 31724969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and facilitators to participate in the colorectal cancer screening programme in Flanders (Belgium): a focus group study.
    Hoeck S; Van Roy K; Willems S
    Acta Clin Belg; 2022 Feb; 77(1):37-44. PubMed ID: 32552612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
    Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
    J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
    Ibáñez-Sanz G; Milà N; Vidal C; Rocamora J; Moreno V; Sanz-Pamplona R; Garcia M;
    PLoS One; 2021; 16(6):e0253369. PubMed ID: 34191813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
    Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
    Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between organised colorectal cancer screening strategies and reduction of its related mortality: a systematic review and meta-analysis.
    Ding H; Lin J; Xu Z; Wang HHX; Huang L; Huang J; Wong MCS
    BMC Cancer; 2024 Mar; 24(1):365. PubMed ID: 38515013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of screening and universal healthcare on long-term colorectal cancer mortality.
    Lee YC; Hsu CY; Chen SL; Yen AM; Chiu SY; Fann JC; Chuang SL; Hsu WF; Chiang TH; Chiu HM; Wu MS; Chen HH
    Int J Epidemiol; 2019 Apr; 48(2):538-548. PubMed ID: 30184208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study.
    Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I
    BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.